^
    6d
    Wondercel-UWD3: Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer (clinicaltrials.gov)
    P1, N=60, Suspended, Wondercel Biotech (ShenZhen) | Recruiting --> Suspended
    Trial suspension
    |
    GPC3 (Glypican 3)
    |
    fludarabine IV
    1m
    GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Baylor College of Medicine
    New P1 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3-CAR and IL15 plus IL21
    2ms
    An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Guangzhou FineImmune Biotechnology Co., LTD.
    New P1 trial
    |
    GPC3 (Glypican 3)
    2ms
    Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Zhejiang University
    New P1 trial
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide
    2ms
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    2ms
    An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Shanghai AbelZeta Ltd.
    New P1 trial
    |
    GPC3 (Glypican 3)
    |
    AZD7003
    4ms
    A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    4ms
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=72, Recruiting, Zhejiang University | N=44 --> 72
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • AZD7003
    4ms
    A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=121, Recruiting, Shanghai AbelZeta Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD7003
    4ms
    GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma (clinicaltrials.gov)
    P1, N=27, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting | Trial completion date: Jun 2044 --> Dec 2044 | Initiation date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jun 2029 --> Dec 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    4ms
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    In-depth plasma proteomics reveals the dynamic changes and prognostic biomarkers for chimeric antigen receptor-glypican-3 T-cell therapy in patients with hepatocellular carcinoma. (PubMed, Gastroenterol Rep (Oxf))
    In addition, plasma proteins were significantly associated with survival outcomes, whereas no significant association was observed between clinical variables and prognosis. Plasma proteomics not only captured CAR-GPC3-driven plasma microenvironment remodeling but also identified baseline proteins predictive of CB and survival, which were superior to clinical variables, thus constituting a candidate biomarker panel for HCC patient selection and response monitoring.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • GPC3 (Glypican 3)
    |
    CT0180